PL3004079T3 - Związki pirymidyny i ich zastosowanie jako modulatorów sekretazy gamma - Google Patents

Związki pirymidyny i ich zastosowanie jako modulatorów sekretazy gamma

Info

Publication number
PL3004079T3
PL3004079T3 PL14727562T PL14727562T PL3004079T3 PL 3004079 T3 PL3004079 T3 PL 3004079T3 PL 14727562 T PL14727562 T PL 14727562T PL 14727562 T PL14727562 T PL 14727562T PL 3004079 T3 PL3004079 T3 PL 3004079T3
Authority
PL
Poland
Prior art keywords
gamma secretase
pyrimidine compounds
secretase modulators
modulators
pyrimidine
Prior art date
Application number
PL14727562T
Other languages
English (en)
Polish (pl)
Inventor
Yevgeni Besidski
Ulrika Yngve
Kim Paulsen
Christian Linde
István MACSÁRI
Jonas MALMBORG
Alexander Paptchikhine
Per Arvidsson
Original Assignee
Acturum Real Estate Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Acturum Real Estate Ab filed Critical Acturum Real Estate Ab
Publication of PL3004079T3 publication Critical patent/PL3004079T3/pl

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
PL14727562T 2013-06-04 2014-06-03 Związki pirymidyny i ich zastosowanie jako modulatorów sekretazy gamma PL3004079T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
SE1350685 2013-06-04
PCT/EP2014/061503 WO2014195323A1 (en) 2013-06-04 2014-06-03 Pyrimidine compounds and their use as gamma secretase modulators
EP14727562.2A EP3004079B1 (en) 2013-06-04 2014-06-03 Pyrimidine compounds and their use as gamma secretase modulators

Publications (1)

Publication Number Publication Date
PL3004079T3 true PL3004079T3 (pl) 2018-07-31

Family

ID=50877325

Family Applications (1)

Application Number Title Priority Date Filing Date
PL14727562T PL3004079T3 (pl) 2013-06-04 2014-06-03 Związki pirymidyny i ich zastosowanie jako modulatorów sekretazy gamma

Country Status (9)

Country Link
US (1) US9439904B2 (enExample)
EP (1) EP3004079B1 (enExample)
JP (1) JP6368777B2 (enExample)
CN (1) CN105263923B (enExample)
DK (1) DK3004079T3 (enExample)
ES (1) ES2665421T3 (enExample)
NO (1) NO3004079T3 (enExample)
PL (1) PL3004079T3 (enExample)
WO (1) WO2014195323A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6975514B2 (ja) * 2016-07-08 2021-12-01 エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft 縮合ピリミジン誘導体
CN108191776A (zh) * 2018-01-22 2018-06-22 无锡富泽药业有限公司 一种尿嘧啶的绿色生产工艺
WO2020247707A1 (en) * 2019-06-05 2020-12-10 Chunyu Wang SYSTEMS AND METHOD FOR INHIBITING γ-SECRETASE PRODUCTION OF AMYLOID-β PEPTIDES
US12297244B2 (en) 2019-06-05 2025-05-13 Rensselaer Polytechnic Institute Systems and methods for inhibiting γ-secretase production of amyloid-β peptides
CN110372603A (zh) * 2019-06-24 2019-10-25 南京普锐达医药科技有限公司 一种2-氯-5-氟-6-乙基嘧啶的合成方法
CN113149977A (zh) 2020-01-22 2021-07-23 苏州爱科百发生物医药技术有限公司 一类呼吸道合胞病毒抑制剂的合成与用途
MX2023011027A (es) 2021-03-23 2023-09-27 Halia Therapeutics Inc Derivados de pirimidina utiles como inhibidores de la proteina cinasa de repeticion 2 rica en leucina (lrrk2).

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002528499A (ja) * 1998-10-29 2002-09-03 ブリストル−マイヤーズ スクイブ カンパニー Impdh酵素のインヒビターであるアミノ核誘導化合物
ITMI20030312A1 (it) 2003-02-21 2004-08-22 Chiesi Farma Spa Derivati di acidi 2-fenil-2-alchil-acetici per il trattamento della malattia di alzheimer.
ATE464048T1 (de) 2003-08-07 2010-04-15 Merck Sharp & Dohme Behandlung von alzheimer-krankheit und verwandten zuständen
JP2007513128A (ja) 2003-12-03 2007-05-24 メルク エンド カムパニー インコーポレーテッド アルツハイマー病および関連状態の治療に有用な1−アルキル−3−チオ置換インドール−2−アルキン酸
US7667041B2 (en) 2004-05-26 2010-02-23 Eisai R&D Management Co., Ltd. Cinnamide compound
MY167260A (en) * 2005-11-01 2018-08-14 Targegen Inc Bi-aryl meta-pyrimidine inhibitors of kinases
CA2649996A1 (en) 2006-04-26 2007-11-08 Merck Sharp & Dohme Limited Piperidines and related compounds for treatment of alzheimer's disease
AU2007252643A1 (en) 2006-05-19 2007-11-29 Eisai R & D Management Co., Ltd. Urea type cinnamide derivative
JP2009184924A (ja) 2006-05-31 2009-08-20 Eisai R & D Management Co Ltd 生物学的試薬用化合物
WO2008097538A1 (en) 2007-02-08 2008-08-14 Merck & Co., Inc. Therapeutic agents
CA2676920A1 (en) 2007-02-12 2008-08-21 Merck & Co., Inc. Piperidine derivatives
CA2676715A1 (en) 2007-02-12 2008-08-21 Merck & Co., Inc. Piperazine derivatives for treatment of ad and related conditions
WO2008156580A1 (en) 2007-06-13 2008-12-24 Merck & Co., Inc. Triazole derivatives for treating alzheimer's disease and related conditions
US20110009392A1 (en) 2007-08-06 2011-01-13 Schering Corporation Gamma secretase modulators
ATE535515T1 (de) 2008-01-11 2011-12-15 Hoffmann La Roche Modulatoren für amyloid beta
RU2010137300A (ru) 2008-02-22 2012-03-27 Ф. Хоффманн-Ля Рош Аг (Ch) Модуляторы бета-амилоида
CN102177151A (zh) * 2008-10-09 2011-09-07 弗·哈夫曼-拉罗切有限公司 β-淀粉样蛋白的调节剂
CN102272133A (zh) 2008-11-06 2011-12-07 阿斯利康(瑞典)有限公司 淀粉样β的调节剂
MX2011004954A (es) 2008-11-10 2011-05-30 Hoffmann La Roche Moduladores heterociclicos de gamma-secretasa.
TW201030002A (en) 2009-01-16 2010-08-16 Bristol Myers Squibb Co Bicyclic compounds for the reduction of beta-amyloid production
UY32622A (es) 2009-05-12 2010-12-31 Astrazeneca Ab Nuevos compuestos para el tratamiento de patologías relacionadas con ab(beta)
EA021047B1 (ru) 2009-07-15 2015-03-31 Янссен Фармасьютикалз, Инк. Замещенные производные триазола и имидазола в качестве модуляторов гамма-секретазы
TWI468402B (zh) 2009-07-31 2015-01-11 必治妥美雅史谷比公司 降低β-類澱粉生成之化合物
MX2012008260A (es) 2010-01-15 2012-08-17 Janssen Pharmaceuticals Inc Novedosos derivados de triazol sustituidos como moduladores de la gamma secretasa.
US20110190269A1 (en) 2010-02-01 2011-08-04 Karlheinz Baumann Gamma secretase modulators
TW201206946A (en) 2010-07-15 2012-02-16 Bristol Myers Squibb Co Compounds for the reduction of beta-amyloid production

Also Published As

Publication number Publication date
NO3004079T3 (enExample) 2018-06-16
ES2665421T3 (es) 2018-04-25
US20160129002A1 (en) 2016-05-12
WO2014195323A1 (en) 2014-12-11
JP2016520637A (ja) 2016-07-14
EP3004079B1 (en) 2018-01-17
EP3004079A1 (en) 2016-04-13
CN105263923A (zh) 2016-01-20
JP6368777B2 (ja) 2018-08-01
CN105263923B (zh) 2017-06-23
US9439904B2 (en) 2016-09-13
DK3004079T3 (en) 2018-04-16

Similar Documents

Publication Publication Date Title
SG11201600028YA (en) Substituted aminopyrimidine compounds and methods of use
IL245733A0 (en) aplnr modulators and their uses
IL240788B (en) Heterocyclic compounds and their uses
PL2951177T3 (pl) Związki imidazopirydynowe i ich zastosowania
IL240466A0 (en) 2-converted azabicycles and their use as orexin receptor modulators
GB201317286D0 (en) Composition and Use
EP3083606A4 (en) Pyrimidines and use thereof
PL3004079T3 (pl) Związki pirymidyny i ich zastosowanie jako modulatorów sekretazy gamma
IL244817B (en) Transmuted pyrimidine compounds and their use as syk inhibitors
IL243957A0 (en) Formulations containing gamma secretase modulators
SG11201604755QA (en) Substituted dihydro-benzimidazole compounds as ror gamma modulators
GB201309180D0 (en) Compounds and Their Uses
IL240177A (en) Chromium-6-Iloxy-cycloalkanes are conserved and used as drugs
GB201314610D0 (en) Compounds and their uses
GB201306248D0 (en) Compounds and their uses
GB201313605D0 (en) Novel compounds and their use
AU2013902560A0 (en) Heterocyclic compounds and their use
EP3013851A4 (en) MODULATORS OF BRADYKININ RECEPTORS AND THEIR USE
GB201320161D0 (en) Compounds and their uses
GB201322467D0 (en) Composition and use
GB201309248D0 (en) Compounds and combinations